期刊
PEDIATRIC BLOOD & CANCER
卷 61, 期 2, 页码 380-382出版社
WILEY-BLACKWELL
DOI: 10.1002/pbc.24756
关键词
c-Met inhibition; developmental therapeutics; preclinical testing
资金
- National Cancer Institute TAK-701 by Millennium Pharmaceuticals [NO1-CM-42216, CA21765]
TAK-701 is a humanized antibody that binds hepatocyte growth factor (HGF), thus suppressing c-Met transduced signaling and c-Met dependent proliferation and migration of tumor cells. Six childhood solid tumor xenografts were selected for evaluating TAK-701 based on immunochemical detection of HGF/c-Met autocrine signaling [i.e., pMet(Tyr1349) and HGF positive]. TAK-701 was tested using a dose of 30mg/kg administered by the intraperitoneal (IP) route twice weekly for 4 weeks. TAK-701 did not induce significant differences in EFS distribution in treated tumors compared to control tumors. Objective responses were not observed in any of the tested solid tumor xenografts. Pediatr Blood Cancer 2014;61:380-382. (c) 2013 Wiley Periodicals, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据